A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome

Conditions

• Presumed Ocular Histoplasmosis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Faricimab Injection [Vabysmo] — DRUG
  Subjects will receive an intravitreal (inside the eye) injection of faricimab 6 mg at the first study visit (loading dose). Subjects will return for monthly study visits for eye exams and imaging and additional faricimab injections may be given on an as-needed basis if specific vision or imaging criteria are met.

Study Details

This study will evaluate the safety and effects, good or bad of faricimab (Vabysmo®), a drug that is approved by the U.S. Food and Drug Administration (FDA) for other retinal conditions, but its use is considered investigational when used specifically for choroidal neovascularization (CNV) related to presumed ocular histoplasmosis (POHS)

Key Dates

First listed

Jul 10, 2026

Start date

Jul 31, 2026

Status verified

Jul 2026

Primary completion

May 31, 2028

Completion

May 31, 2028

Study Design

Enrollment

25 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Active Comparator: Treatment
  an intravitreal (inside the eye) injection of faricimab 6 mg at the first study visit (loading dose).

Primary Outcome Measure

CST Value [ Time Frame: 52 weeks ]

Central Contacts

• Kelye Conrad, Clinical Research Manager
  1+513-569-3688
  [email protected]

Locations (2)

Find similar trials in Cincinnati, OH